Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)-Reference-Cited by-同舟云学术

Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

Published:2023-10 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Damassi Alessandra,Cremante Malvina^ORCID,Signori Alessio,Rebuzzi Sara Elena^ORCID,Fornarini Giuseppe,Giudice Giulia Claire^ORCID,Maruzzo Marco^ORCID,Procopio Giuseppe,Sorarù Mariella^ORCID,Di Napoli Marilena,Fratino Lucia,Santini Daniele,Grillone Francesco^ORCID,Ballestrin Melissa,Dionese Michele^ORCID,Nasso Cecilia,Catalano Fabio^ORCID,Murianni Veronica^ORCID,Rescigno Pasquale,Anpalakhan Shobana,Banna Giuseppe Luigi^ORCID,Basso Umberto,Buti Sebastiano^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference18 articles.

1. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor;Markowitz;Pharmacotherapy,2018

2. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial;Choueiri;J Clin Oncol,2017

3. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update;Choueiri;Eur J Cancer Oxf Engl,2018

4. Cabozantinib versus everolimus in advanced renal-cell carcinoma;Choueiri;N Engl J Med,2015

5. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma;European Journal of Cancer;2024-07